Victory Capital Management
EVOK

Victory Capital Management’s Evoke Pharma EVOK Stock Holding History

Victory Capital Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-27
Closed -$4K – 2757
2020
Q1 		$4K Buy
+27
New +$5.19K ﹤0.01% 3342
2019
Q4 		– Sell
-26
Closed -$3K – 2842
2019
Q3 		$3K Buy
+26
New +$3.48K ﹤0.01% 3554

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WA
Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Victory Capital Management's EVOK Position: Q2 2020 in Review

Victory Capital Management sold out of Evoke Pharma (EVOK) in Q2 2020, closing a stake of 27 shares — an estimated $4K sold.

Victory Capital Management first reported a position in EVOK in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 19 funds tracked by Wall St. Rank hold EVOK as of Q2 2020.

  • Victory Capital Management reported no remaining Evoke Pharma position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 27 Evoke Pharma shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in Evoke Pharma in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Evoke Pharma position peaked at $4K in Q1 2020.
  • 19 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.